DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
November 21, 2024 09:00 ET
|
DANNCE.AI
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform.
Adia Nutrition Secures Lease for First Clinic in Winter Park, Florida
October 29, 2024 09:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. proudly announces the signed lease for their state-of-the-art clinic, set to open in the distinguished Winter Park Medical...
Adia Nutrition Inc. Takes Major Steps Forward: Signs LOI for First Clinic and Engages Legal Expertise for Licensing
October 15, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is proud to announce a groundbreaking initiative in the fight against Multiple Sclerosis (MS) with the signing of...
Appointment of Dr. Kalpesh Barot, MD Completes Phase One of ADIA Nutrition’s Medical Division
September 24, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition (OTC Pink: ADIA) is excited to announce the completion of its Board of Medical Directors with the appointment of Dr. Kalpesh...
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion
September 17, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property...
ADIA Nutrition Appoints Dr. Richard Edwards, DO as Second Medical Director
September 10, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is excited to announce the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards...
Tiziana Life Sciences Appoints New Chief Executive Officer
August 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Granted FDA Fast Track Designation
July 24, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
July 16, 2024 08:37 ET
|
Trethera Corporation
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
June 11, 2024 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...